Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Rating) in a report released on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $8.00 price objective on shares of Minerva Neurosciences in a report on Thursday, March 9th.

Get Minerva Neurosciences alerts:

Minerva Neurosciences Price Performance

NASDAQ NERV opened at $1.63 on Monday. The company has a market cap of $8.70 million, a P/E ratio of -0.27 and a beta of 0.06. The stock has a 50-day moving average of $2.06 and a two-hundred day moving average of $3.42. Minerva Neurosciences has a 1-year low of $1.26 and a 1-year high of $15.27.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its holdings in Minerva Neurosciences by 8.3% during the 4th quarter. Renaissance Technologies LLC now owns 110,300 shares of the biopharmaceutical company’s stock worth $175,000 after buying an additional 8,500 shares during the last quarter. BlackRock Inc. grew its stake in shares of Minerva Neurosciences by 54.7% in the 3rd quarter. BlackRock Inc. now owns 78,086 shares of the biopharmaceutical company’s stock valued at $721,000 after purchasing an additional 27,612 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Minerva Neurosciences in the 3rd quarter valued at $231,000. Truist Financial Corp acquired a new position in Minerva Neurosciences in the 3rd quarter valued at $102,000. Finally, UBS Group AG boosted its holdings in shares of Minerva Neurosciences by 914.5% in the third quarter. UBS Group AG now owns 5,732 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 5,167 shares in the last quarter. 38.00% of the stock is owned by institutional investors and hedge funds.

Minerva Neurosciences Company Profile

(Get Rating)

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease.

Read More

• Get a free copy of the StockNews.com research report on Minerva Neurosciences (NERV)
• MarketBeat Week in Review – 4/3 – 4/7
• Costco Sales Disappoint, Markets Are Missing This Upside Driver
• First Republic Bank Is A Speculative Play, Here’s Why
• The WD-40 Company Bottoms With Reversal In Sight 
• 3 Low-Cost Stock ETFs That Are Crushing It This Year

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.